Astrazeneca suggests Trump Price's cuts in the US drugs

The office building of the international biopharmaceutical company Astrazeneca.

CFOTO | Future publication | Getty pictures

A version of this article was first published in CNBCS Healthy Return's newsletter, in which the latest health news leads directly to their inbox. Subscribe here to get future expenses.

President Donald Trump has put pharmaceutical companies under pressure to reduce the US drug costs, and it can possibly work – at least Astrazeneca.

Astrazeneca proposed certain drugs in the USA, his CEO Pascal Soriot told reporters on Tuesday after the company's sales and profits had taken over the estimates in the second quarter.

“We have made suggestions for what we, as a company, believe that it could be done, which actually balanced the pricing with a reduction in the United States,” said Soriot and at the same time found that the price dynamics in the country is “very complicated” and has no transparency.

He said the Trump administration checked the company's proposals, but did not indicate which treatments it contained. Astrazeneca seems to be one of the first drug makers that revealed that the Trump administration has recorded the price reductions.

“I believe that a new compensation for pricing around the world is necessary. The United States can no longer pay for the research and development of the world,” said Pascal.

“We definitely support the idea of exploiting with some reduction in the price level in the USA, and some increase, we are not talking about massive increases in Europe,” he continued.

The company has previously set itself the goal of generating sales of $ 80 billion by the end of the decade, with 50% of them or around 40 billion US dollars from the United States

Why now?

Sorio's comments come two months after Trump signed a comprehensive execution regulations that aimed at renewing a plan to reduce the US medicinal products by prices in other industrialized countries. Trump described the efforts – referred to as “most preferred nation” policy – as “compensation prices”.

We can also not forget the planned tariffs of the President for pharmaceuticals imported in the USA what could happen every day and have the consequences for pharmaceutical manufacturers and patients. The taxes aim to increase the production of domestic medications, even after Astrazeneca and other companies have announced new US investments in billions of dollars in the past few months.

Astrazeneca announced last week that it should invest $ 50 billion in strengthening its US manufacturing and research skills by 2030, including new locations and expansion of previous investments.

Soriot also said on Tuesday that he expects all of Astrazeneca to be produced on site for US patients within a few months.

He added that the company is considering selling some medication directly to patients – a step that companies such as Eli Lilly, Novo Nordisk, Pfizer and Bristol Myers Squibb have difficulty affecting medication

“We want to behave as a US company in the USA,” said Soriot.

But he added that the Astrazeneca, based in Great Britain, was “committed” to his home country, which is in the middle of reports that the company is considering moving its list in the States.

Pascal refused to comment on the rumors about the company's profit call in the second quarter.

Feel free to send Annikakim.constantino@nbcuni.com tips, suggestions, ideas and data to Annika.

Latest in the healthcare system Tech: Doximity occurs competitive AI writing market with a new free offer

Last week, Doximity announced a new tool called doximity scribe, a free documentation solution for artificial intelligence, with which clinicians are supposed to help the time they spend on paperwork.

The company is the youngest, which immerse yourself in the heavily competitive AI writing market and has taken on the healthcare managers according to opportunities to reduce employees and discouraging administrative workload.

As with other tools on the market, Doximity Skribe AI uses to design clinical notes in real time, while the doctors determine their visits with the patient's permission. By offering the tool free of charge, Doximity follows a different approach than its competitors such as Microsoft, and others.

“Comparable writing services can cost hundreds of dollars per user and month,” said Doximity in a publication. “We believe that powerful tools like this should be accessible to all clinicians, not just for those with the budgets.”

Doximity is a digital platform for medical specialists that helps clinicians to stay up to date in medical news, find paperwork, to find transfers and to carry out telemedical appointments with patients. The company mainly achieves income through its hiring solutions and marketing for customers such as pharmaceutical companies.

In addition to doximity scribe, the company offers clinicians a AI tool called DOXIMITY GPT as well as a video and telemedicine platform called doximity dialer. In other words, this game book follows before.

But while the free offer will probably attract many clinicians, it may not yet be in the head.

Several other players in the room, including Microsoft and move away, can support deep integrations with providers from Electronic Health Record, while Doximity Skrib begins with a beta integration with its own product, the dialer. Similarly, Doximity users can choose between structured templates or freeform notes, but other providers offer support for the specialty of a provider as well as additional functions for coding and billing.

As a result, large, complex health systems will still be willing to pay AI script scholars at least for the time being.

Doximity said it would have an impact on its writer in the coming months, and clinicians can register for early access.

Read the complete announcement here.

Feel free to send tips, suggestions, story ideas and data to Ashley at Ashley.capoot@nbcuni.com.